Out of a hundred COVID-19 patients, less than five percent will experience severe disease, hospitalization, ventilation and mortality . A number of risk factors have been proposed and validated in wide population studies, and include age, smoking history and diabetes. However, each of these factors lack the sufficient sensitivity and specificity to support the early detection of patients at high risk of severe COVID-19. Additionally, in patients who already present with moderate to severe COVID-19, physicians lack effective and accessible tools to monitor disease deterioration or response to treatment. Given COVID-19’s high correlation with a patient’s immune response, new host immune response measurement technologies are showing promise in changing the paradigm of COVID-19 patient stratification and management.

Researchers at Israel’s Rabin Medical Center, in collaboration with MeMed, have published prospective data on the potential utility of a 15-minute point of need solution that measures TRAIL and IP-10, two viral-induced host immune biomarkers, in stratifying patients with severe COVID-19 and managing their treatment. This data, in addition to a decade-long series of studies on dozens of other respiratory viral infections, shows that serial measurements of the viral-induced immune proteins TRAIL and IP-10 can be a valuable resource for predicting disease severity and progression, and for monitoring individual patient responses to treatment for severe COVID-19.

In this session, Dr. Kfir Oved will discuss the study findings, as well as recent advances in the technologies used to probe the host response to infection, particularly those based on proteomics. The session will also highlight how predictive biomarkers and the actionable insights they provide can potentially be used to improve COVID-19 patient management, enabling interventions that can help reduce ICU admissions, the need for ventilation and, ultimately, mortality.


Dr. Kfir Oved has over 15 years of combined industry and academic experience, leading interdisciplinary teams combining biotechnology and biochemistry, applied immunology, engineering, and big data in multiple clinical applications. Kfir co-founded MeMed and serves as its Chairman of the Board. For over a decade, he served as CTO of MeMed, where he led the inception, development, and clinical validation of the entire MeMed technology suite, including the MeMed BV™ test, and the MeMed Key™ point-of-need platform, from an idea on a napkin to development completion.
Dr. Oved holds a B.A. in Biology (Summa Cum Laude), B.Sc. in medicine (Magna Cum Laude), and Ph.D. in molecular immunology, and trained for six years at the Technion School of Medicine. Dr. Oved is the co- author of over 100 granted and pending patents, the author of over 20 peer-reviewed publications, and the recipient of multiple research excellence awards, including the Gutwirth Excellence award an Wolf Award for research students. In 2019, he was listed among the top 25 voices in precision medicine by BIS research. Dr. Oved is among the inceptors of the AI-based health data company Navina and serves as its Chief Strategy and Innovation Officer. Last year, he founded Canopy Immuno-Therapeutics, a stealth mode biotech company engaged in developing a novel immunotherapeutic approach for autoimmunity and life-threatening allergy.